HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue; 75% Increase From Second Quarter Of 2012
FRAMINGHAM, Mass. and SYDNEY, Aug. 8, 2013 /PRNewswire/ -- HeartWare International, Inc.(NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $50.8 million for the second quarter ended June 30, 2013, a 75% increase compared to$29.1 million in revenue for the same period of 2012.
"Our results for the second quarter reflect positive initial trends in the commercial launch of theHeartWare® Ventricular Assist System in the U.S., following approval from the Food and Drug Administration (FDA) late last year, as well as continued strong support from our international customers," said Doug Godshall, President and Chief Executive Officer. "During the second quarter, 523 HVAD® pumps were sold globally, an increase from 318 units in the second quarter of 2012 and more than our previous high quarterly total of 482 units in the first quarter of 2013."
During the second quarter of 2013, U.S. revenue, which reflects the Company's second full quarter of U.S. commercialization, was $25.1 million, an increase of approximately 500% from $4.2 million in the second quarter of 2012. Revenue from international markets, generated through the sale of 288 units, was $25.7 million, an increase of approximately 4% from $24.9 million in the second quarter of 2012.
"With more than 200 customers around the world, including 120 outside of the U.S., at the end of the second quarter, it continues to be quite gratifying to see such strong interest from new hospital centers thus far in our commercial launch," added Mr. Godshall. "Our team has been focused on facilitating the training of additional U.S. hospitals as part of the continued commercial launch, and with 33 new sites trained between FDA approval and the end of the second quarter, we finished the first half of 2013 with 83 customers in the U.S."
For the six months ended June 30, 2013, revenues increased approximately 81% to $100.1 million, compared to $55.4 million in the first six months of 2012.
Currency fluctuations had a less than 1% favorable impact on revenue growth for both the three and six months ended June 30, 2013 compared to the same period in 2012.
Total operating expenses for the second quarter of 2013 were $41.4 million, as compared to $34.2 million in the second quarter of 2012.
Research and development expense was $24.2 million for the second quarter of 2013, as compared to $20.0 million in the same period of 2012. Development costs are primarily attributable to clinical trial costs and research and development costs related to advancing HeartWare's pipeline technologies, including the MVAD® platform, PAL™ controller and a fully-implantable system, as well as other early research initiatives.
Selling, general and administrative expenses were $17.2 million in the second quarter of 2013, compared to $14.2 million in the second quarter of 2012. The increase in selling, general and administrative expenses reflects expansion of sales and marketing activities, particularly in the U.S., an overall increase in corporate infrastructure to support the Company's significant growth, and implementation of the 2.3% excise tax on the U.S. sales of certain medical devices which became effective January 1, 2013.
Net loss for the second quarter of 2013 was $12.9 million, or a $0.79 loss per basic and diluted share, compared to a $22.8 million net loss, or a loss of $1.61 per basic and diluted share, in the second quarter of 2012. For the six months ended June 30, 2013, the Company recorded a net loss of $25.9 million, or a $1.66 loss per basic and diluted share, compared to a $41.6 million net loss, or a loss of$2.94 per basic and diluted share, in the first six months of 2012.
At June 30, 2013, the Company had $222.4 million of cash, cash equivalents and investments, reflecting a net cash decrease from the end of the first quarter 2013 of approximately $6.5 million.
HeartWare will host a conference call on Thursday, August 8, 2013 at 8:00 a.m., U.S. Eastern Daylight Time to discuss the Company's financial results, highlights from the second quarter and business outlook. The call may be accessed by dialing 1-877-941-2321 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial +1-480-629-9666.
A live webcast of the call will also be available in the Investor section at the Company's website (http://ir.heartware.com/). A replay of the conference call will be available through the above weblink immediately following completion of the call.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. TheHeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 35 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the commercial launch of the HeartWare® Ventricular Assist System in the U.S., continued support from international customers, progress of clinical trials and post-approval studies, regulatory status, research and development activities and commercialization strategies. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in Part I, Item 1A. "Risk Factors" in HeartWare's Annual Report on Form 10-K filed with the Securities and Exchange Commission. HeartWare may update risk factors from time to time in Part II, Item 1A "Risk Factors" in Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.
For further information:
HeartWare International, Inc.
Phone: +1 508 739 0864